tiprankstipranks
Advertisement
Advertisement

RNAC Stock Latest News

Cartesian Therapeutics management to meet with BTIG
The FlyCartesian Therapeutics management to meet with BTIG
6d ago
RNAC
Buy Rating on Cartesian Therapeutics (RNAC) Driven by Strong Strategic Vision, Clinical Roadmap, and Attractive Risk‑Reward Profile
PremiumRatings
Buy Rating on Cartesian Therapeutics (RNAC) Driven by Strong Strategic Vision, Clinical Roadmap, and Attractive Risk‑Reward Profile
20d ago
RNAC
Cartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation
PremiumCompany Announcements
Cartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation
1M ago
8K
RNAC
RNAC’s Descartes-08 Moves Toward Phase 2 in Rare Muscle Disease: What Investors Should Watch
PremiumCompany Announcements
RNAC’s Descartes-08 Moves Toward Phase 2 in Rare Muscle Disease: What Investors Should Watch
2M ago
RNAC
Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
PremiumThe Fly
Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
2M ago
RNAC
Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
PremiumThe FlyCartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
2M ago
RNAC
Cartesian Therapeutics: Reaffirmed AURORA Timelines and Solid Cash Runway Underpin Needham Buy Rating and $42 Target
Premium
Ratings
Cartesian Therapeutics: Reaffirmed AURORA Timelines and Solid Cash Runway Underpin Needham Buy Rating and $42 Target
2M ago
RNAC
Cartesian Therapeutics reports FY25 EPS ($5.02), consensus ($2.35)
Premium
The Fly
Cartesian Therapeutics reports FY25 EPS ($5.02), consensus ($2.35)
2M ago
RNAC
RNAC Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
RNAC Upcoming Earnings Report: What to Expect?
2M ago
RNAC
Cartesian Therapeutics announces employment inducement grants
PremiumThe Fly
Cartesian Therapeutics announces employment inducement grants
3M ago
RNAC
Cartesian Therapeutics Outlines 2026 Outlook and Trial Progress
PremiumCompany Announcements
Cartesian Therapeutics Outlines 2026 Outlook and Trial Progress
4M ago
8K
RNAC
Cartesian Therapeutics highlights recent progress, outlines 2026
PremiumThe Fly
Cartesian Therapeutics highlights recent progress, outlines 2026
4M ago
RNAC
Cartesian Therapeutics announces employment inducement grants
PremiumThe FlyCartesian Therapeutics announces employment inducement grants
4M ago
RNAC
Strategic Positioning and Unique Treatment Profile Drive Buy Rating for Cartesian Therapeutics
Premium
Ratings
Strategic Positioning and Unique Treatment Profile Drive Buy Rating for Cartesian Therapeutics
5M ago
RNAC
Strategic Pivot and Promising Clinical Data Justify Buy Rating for Cartesian Therapeutics
Premium
Ratings
Strategic Pivot and Promising Clinical Data Justify Buy Rating for Cartesian Therapeutics
5M ago
RNAC
H.C. Wainwright cuts Cartesian target, calls shares ‘mispriced’
PremiumThe Fly
H.C. Wainwright cuts Cartesian target, calls shares ‘mispriced’
6M ago
RNAC
Strategic Realignment Boosts Cartesian Therapeutics’ Prospects: Gil Blum Issues Buy Rating
PremiumRatings
Strategic Realignment Boosts Cartesian Therapeutics’ Prospects: Gil Blum Issues Buy Rating
6M ago
RNAC
Cartesian Therapeutics price target raised to $44 from $42 at BTIG
PremiumThe Fly
Cartesian Therapeutics price target raised to $44 from $42 at BTIG
6M ago
RNAC
Cartesian Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
Cartesian Therapeutics Reports Q3 2025 Financial Results
6M ago
RNAC
Cartesian announces positive initial data from Phase 2 SLE trial of Descartes-08
PremiumThe FlyCartesian announces positive initial data from Phase 2 SLE trial of Descartes-08
6M ago
RNAC
Cartesian Therapeutics Reports Promising Phase 2 Trial Results
Premium
Company Announcements
Cartesian Therapeutics Reports Promising Phase 2 Trial Results
6M ago
8K
RNAC
Cartesian Therapeutics reports Q3 EPS ($1.38) vs ($1.13) last year
Premium
The Fly
Cartesian Therapeutics reports Q3 EPS ($1.38) vs ($1.13) last year
6M ago
RNAC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >